Diamyd Medical AB’s Licensee Reports Progress with GAD in Parkinson
STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:
Neurologix Inc., a biotech company engaged in gene therapy, reports that they have initiated a Phase II study with the GAD-gene within Parkinson’s disease. The right to use the GAD-gene has been licensed from Diamyd (Pink Sheets:DMYDY) (STO:DIAMB).